UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Volltextzugriff (PDF)

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers

International journal of oncology, 2022-03, Vol.60 (3), p.1, Article 35

2022

Volltextzugriff (PDF)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Volltextzugriff (PDF)

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Current opinion in urology, 2020-01, Vol.30 (1), p.98-105

2020

Volltextzugriff (PDF)

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.891-899

Davis, T. M. E.

2014

Volltextzugriff (PDF)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Archives of Endocrinology and Metabolism, 2018-08, Vol.62 (4), p.424-430

2018

Volltextzugriff (PDF)

Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury

Molecular medicine reports, 2020-07, Vol.22 (1), p.33-42

2020

Volltextzugriff (PDF)

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

Oncotarget, 2016-10, Vol.7 (43), p.69625-69637

2016

Volltextzugriff (PDF)

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation

World journal of gastroenterology : WJG, 2015-06, Vol.21 (24), p.7436-7442

2015

Volltextzugriff (PDF)

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Volltextzugriff (PDF)

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Volltextzugriff (PDF)

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Revista española de cardiología (English ed.), 2017-12, Vol.70 (12), p.1143-1144

2017

Volltextzugriff (PDF)

Saxagliptin efficacy

Diabetes, obesity & metabolism, 2010-08, Vol.12 (8), p.734-734

Valiquette, G.

2010

Volltextzugriff (PDF)

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

IDrugs : the investigational drugs journal, 2008-12, Vol.11 (12), p.906

Gallwitz, Baptist

2008

Volltextzugriff (PDF)

Alanyl-glutamine dipeptide inhibits hepatic ischemia-reperfusion injury in rats

World journal of gastroenterology : WJG, 2006-03, Vol.12 (9), p.1373

2006

Volltextzugriff (PDF)

Role of cathepsin B-mediated apoptosis in fulminant hepatic failure in mice

World journal of gastroenterology : WJG, 2009-03, Vol.15 (10), p.1231-1236

2009

Volltextzugriff (PDF)

Confocal Raman Spectral Imaging Study of DAPT, a γ-secretase Inhibitor, Induced Physiological and Biochemical Reponses in Osteosarcoma Cells

International journal of medical sciences, 2020-01, Vol.17 (5), p.577-590

2020

Volltextzugriff (PDF)

No heart risk--or benefit--from diabetes drug Onglyza

Harvard heart letter, 2013-12, Vol.24 (4), p.8

2013

Volltextzugriff (PDF)

A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis

Chemistry & biology, 2012-09, Vol.19 (9), p.1142-1151

2012

Volltextzugriff (PDF)

Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma

Nuklearmedizin. Nuclear medicine, 2019-08, Vol.58 (4), p.328

2019

Volltextzugriff (PDF)

Protective effects of alanyl-glutamine on acute lung injury induced by lipopolysaccharide in rats

Zhong nan da xue xue bao. Journal of Central South University. Yi xue ban, 2008-12, Vol.33 (12), p.1095-1100

2008

Volltextzugriff (PDF)

Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment

IDrugs : the investigational drugs journal, 2007-08, Vol.10 (8), p.566

2007

Volltextzugriff (PDF)

Value of post-therapy 177 Lu-PSMA images for accurate interpretation of therapy response with 68 Ga-PSMA PET/CT

Revista espanola de medicina nuclear e imagen molecular, 2018-03, Vol.37 (2), p.114

2018

Volltextzugriff (PDF)

Novel neuroendocrine and metabolic mechanism provides the patented platform for important rejuvenation therapies: targeted therapy of telomere attrition and lifestyle changes of telomerase activity with the timing of neuron-specific imidazole-containing dipeptide-dominant pharmaconutrition provision

Recent patents on endocrine, metabolic & immune drug discovery, 2014-01, Vol.8 (3), p.153-179

2014

Volltextzugriff (PDF)

Saxagliptin in type 2 diabetes

Drugs of Today, 2010-02, Vol.46 (2), p.101-108

Billiones, Raquel

2010

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCurrent Opinion In Investigational Drugs

Nur zeigenGeprüft (Peer-Review)

ThemaAged

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(39)

Publikationsform

Erscheinungsjahr

n.n

Thema

Dipeptides - Therapeutic Use
(67)
Science & Technology
(59)
Life Sciences & Biomedicine
(57)
Humans
(56)
Animals
(41)
Male
(31)
Dipeptides - Pharmacology
(25)
Adamantane - Analogs & Derivatives
(20)
Diabetes Mellitus, Type 2 - Drug Therapy
(20)
Rats
(18)
Female
(17)
Adamantane - Therapeutic Use
(16)
Pharmacology & Pharmacy
(16)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(15)
Treatment Outcome
(14)
Dipeptides - Adverse Effects
(13)
Hypoglycemic Agents - Therapeutic Use
(13)
Mice
(13)
Endocrinology & Metabolism
(12)
Adult
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation

Baseline differences in the SAVOR trial

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Saxagliptin efficacy

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Alanyl-glutamine dipeptide inhibits hepatic ischemia-reperfusion injury in rats

Role of cathepsin B-mediated apoptosis in fulminant hepatic failure in mice

Confocal Raman Spectral Imaging Study of DAPT, a γ-secretase Inhibitor, Induced Physiological and Biochemical Reponses in Osteosarcoma Cells

No heart risk--or benefit--from diabetes drug Onglyza

A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis

Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma

Protective effects of alanyl-glutamine on acute lung injury induced by lipopolysaccharide in rats

Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment

Value of post-therapy 177 Lu-PSMA images for accurate interpretation of therapy response with 68 Ga-PSMA PET/CT

Novel neuroendocrine and metabolic mechanism provides the patented platform for important rejuvenation therapies: targeted therapy of telomere attrition and lifestyle changes of telomerase activity with the timing of neuron-specific imidazole-containing dipeptide-dominant pharmaconutrition provision

Saxagliptin in type 2 diabetes

Aktive Filter

Suchergebnisse filtern